Experience with the use of recombinant humanized monoclonal antibodies to the human receptor for interleukin-6 in patients with CoVID-19
The new coronavirus infection (COVID-19) has become a truly global challenge for all of humanity, and, above all, for the healthcare system. Among its most important aspects requiring careful analysis are the clinical and laboratory features of the course of the disease, which make it possible to de...
Saved in:
| Main Authors: | D. А. Gusev, М. А. Vashukova, I. P. Feduniak, V. B. Musatov, V. A. Kapatsyna |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Journal Infectology
2020-08-01
|
| Series: | Журнал инфектологии |
| Subjects: | |
| Online Access: | https://journal.niidi.ru/jofin/article/view/1074 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Issues of pathology of a new coronavirus infection CoVID-19
by: V. A. Zinserling, et al.
Published: (2020-06-01) -
Pathogenetic therapy in patients with COVID-19
by: V. A. Kapatsina, et al.
Published: (2022-10-01) -
Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody
by: Yasuaki Tomioka, et al.
Published: (2021-09-01) -
Clinical and pathological analysis of deaths from different SARS-CoV-2 coronavirus genotypes
by: M. A. Vashukova, et al.
Published: (2022-10-01) -
Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6
by: Evgeny L. Nasonov, et al.
Published: (2024-09-01)